In the present study, serum LIF levels were significantly reduced in the TKI-targeted treatment group of NSCLC patients, possibly due to the participation of LIFR in the binding of gp130 to the JAK-Tyk family of cytoplasmic tyrosine kinases [58], the detailed mechanism of which should be further explored. This evidence concerns the gene LIF and non-small cell lung carcinoma.